Cytochrome P450 CYP1B1 activity in renal cell carcinoma

British Journal of Cancer

Volumn 91, Issue 5, 2004, Pages 966-971

  McFadyen, M C E ^a   Melvin, W T ^a   Murray, G I ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

CYP1B1; P450 reductase; Renal cell carcinoma; Therapeutic intervention; Tumour

Indexed keywords

ACRIVASTINE; ALKYLATING AGENT; ALPHA INTERFERON; ALPHA NAPHTHOFLAVONE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTOCHROME C; CYTOCHROME P450 1B1; CYTOCHROME P450 1B1 INHIBITOR; CYTOCHROME P450 INHIBITOR; CYTOCHROME P450 REDUCTASE; DOCETAXEL; ETHOXYRESORUFIN; IFOSFAMIDE; INTERLEUKIN 2; MELPHALAN; MULTIDRUG RESISTANCE PROTEIN; NIFEDIPINE; NITROSOUREA DERIVATIVE; QUINIDINE; RESORUFIN; UNCLASSIFIED DRUG; VALSPODAR; VERAPAMIL; VINBLASTINE;

ADULT; AGED; ARTICLE; BIOTRANSFORMATION; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CATALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; GENE OVEREXPRESSION; HUMAN; INCUBATION TIME; KIDNEY CANCER; KIDNEY CARCINOMA; METABOLIC REGULATION; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; ARYL HYDROCARBON HYDROXYLASES; CARCINOMA, RENAL CELL; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; HUMANS; KIDNEY; KIDNEY NEOPLASMS; MICROSOMES; MIDDLE AGED; NADPH-FERRIHEMOPROTEIN REDUCTASE; OXAZINES;

EID: 4644346406     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602053     Document Type: Article

References (43)

1. Bournique B, Lemarie A (2002) Docetaxel (Taxotere) is not metabolized by recombinant human CYP1B1 in vitro, but acts as an effector of this isozyme. Drug Metab Dispos 30: 1149-1152
2. Bradford M (1976) A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principles of protein-dye binding. Anal Biochem 74: 248-254
3. Burke MD, Mayer RT (1974) Ethoxyresorufin: direct fluorimetric assay of a microsomal O-dealkylation which is preferentially inducible by 3-methylcholanthrene. Drug Metab Dispos 2: 583-588
4. Chang TK, Lee WB, Ko HH (2000) Trans-resveratrol modulates the catalytic activity and mRNA expression of the procarcinogen-activating human cytochrome P450 1B1. Can J Physiol Pharm 78: 874-881
5. Chang TKH, Chen J, Pillay V, Ho J-Y, Bandiera SM (2003) Real-time polymerase chain reaction analysis of CYP1B1 gene expression in human liver. Toxicol Sci 71: 11-19
6. Chapman AE, Goldstein LJ (1995) Multiple drug resistance: biological basis and clinical significance in renal cell carcinoma. Semin Oncol 22: 17-28
7. Cheung YL, Kerr AC, McFadyen MC, Melvin WT, Murray GI (1999) Differential expression of CYP1A1, CYP1A2, CYP1B1 in human kidney tumours. Cancer Lett 139: 199-205
8. Djordjevic S, Roberts DL, Wang M, Shea T, Camitta MG, Masters BS, Kim JJ (1995) Crystallization and preliminary X-ray studies of NADPH-cytochrome P450 reductase. Proc Natl Acad Sci USA 92: 3214-3218
9. Edwards RJ, Adams DA, Watts PS, Davies DS, Boobis AR (1998) Development of a comprehensive panel of antibodies against the major xenobiotic metabolising forms of cytochrome P450 in humans. Biochem Pharmacol 56: 377-387
10. Fujita K, Kamataki T (2001) Role of human cytochrome P450 (CYP) in the metabolic activation of N-alkylnitrosamines: application of genetically engineered Salmonella typhimurium YG7108 expressing each form of CYP together with human NADPH-cytochrome P450 reductase. Mutat Res 483: 35-41
11. Gattinoni L, Alu M, Ferrari L, Nova P, Del Vecchio M, Procopio G, Laudani A, Agostara B, Bajetta E (2003) Renal cancer treatment: a review of the literature. Tumori 89: 476-484
12. Gibson P, Gill JH, Khan PA, Seargent JM, Martin SW, Batman PA, Griffith J, Bradley C, Double JA, Bibby MC, Loadman PM (2003) Cytochrome P450 1B1 (CYP1B1) is overexpressed in human colon adenocarcinomas relative to normal colon: implications for drug development. Mol Cancer Ther 2: 527-534
13. Gnarra JR, Lerman MI, Zbar B, Linehan WM (1995) Genetics of renal-cell carcinoma and evidence for a critical role for von Hippel-Lindau in renal tumorigenesis. Semin Oncol 22: 3-8
14. Gut I, Danielova V, Holubova J, Soucek P, Kluckova H (2000) Cytotoxicity of cyclophosphamide, paclitaxel, and docetaxel for tumor cell lines in vitro: effects of concentration, time and cytochrome P450-catalyzed metabolism. Arch Toxicol 74: 437-446
15. Henderson CJ, Otto DME, McLaren AW, Corrie D, Wolf CR (2003) Knockout mice in xenobiotic metabolism. Drug Metab Rev 35: 385-392
16. ISD. http://www.isdscotland.org/isd/info3.jsp?pContentID = 1507&a_applic = CCC&p_service=Content.show&. ISD: Scottish Cancer statistics web site accessed 15th January 2004
17. Kajita J, Kuwabara T, Kobayashi H, Kobayashi S (2000) CYP3A4 is mainly responsible for the metabolism of a new vinca alkaloid, vinorelbine, in human liver microsomes. Drug Metab Dispos 28: 1121-1127
18. Kovacs G, Akhtar M, Beckwith BJ, Bugert P, Cooper CS, Delahunt B, Eble JN, Fleming S, Ljungberg B, Medeiros LJ, Moch H, Reuter VE, Ritz E, Roos G, Schmidt D, Srigley JR, Storkel S, van den Berg E, Zbar B (1997) The Heidelberg classification of renal cell tumours. J Pathol 183: 131-133
19. Lewis DF, Ioannides C, Parke DV (2003) A quantitative structure-activity relationship (QSAR) study of mutagenicity in several series of organic chemicals likely to be activated by cytochrome P450 enzymes. Teratogen Carcingen Mutat 23: 187-193
20. Lineham WM, Shipley WU, Parkinson DR (1997) Cancer of the kidney and ureter. In Cancer, Principles and Practice of Oncology, De Vita VT, Hellman S, Rosenburg S (eds) pp 1271-1300, Philadelphia: Lippincott-Raven
21. López de Cerain A, Marin A, Idoate MA, Tunon MT, Bello J (1999) Carbonyl reductase and NADPH-cytochrome P450 reductase activities in human tumoral versus normal tissues. Eur J Cancer 35: 320-324
22. Lu AYH, Coon MJ (1968) Role of hemoprotein P-450 in fatty acid hydroxylation in a soluble enzyme system from liver microsomes. J Biol Chem 243: 1331-1332
23. Lu AYH, Junk KW, Coon MJ (1969) Resolution of the cytochrome P-450-containing hydroxylation system of liver microsomes into three components. J Biol Chem 244: 3714-3721
24. McFadyen MC, Breeman S, Payne S, Stirk C, Miller ID, Melvin WT, Murray GI (1999) Immunohistochemical localization of cytochrome P450 CYP1B1 in breast cancer with monoclonal antibodies specific for CYP1B1. J Histochem Cytochem 47: 1457-1464
25. McFadyen MC, Cruickshank ME, Miller ID, McLeod HL, Melvin WT, Haites NE, Parkin D, Murray GI (2001a) Cytochrome P450 CYP1B1 over-expression in primary and metastatic ovarian cancer. Br J Cancer 85: 242-246
26. McFadyen MC, McLeod HL, Jackson FC, Melvin WT, Doehmer J, Murray GI (2001b) Cytochrome P450 CYP1B1 protein expression: a novel mechanism of anticancer drug resistance. Biochem Pharmacol 62: 207-212
27. McFadyen MC, Melvin WT, Murray GI (2004) Cytochrome P450 enzymes: novel options for cancer therapeutics. Mol Cancer Ther 3: 363-371
28. Murray GI (2000) The role of cytochrome P450 in tumour development and progression and its potential in therapy. J Pathol 192: 419-426
29. Murray GI, McFadyen MC, Mitchell RT, Cheung YL, Kerr AC, Melvin WT (1999) Cytochrome P450 CYP3A in human renal cell cancer. Br J Cancer 79: 1836-1842
30. Murray GI, Melvin WT, Greenlee WF, Burke MD (2001) Regulation, function, and tissue-specific expression of cytochrome P450 CYP1B1. Annu Rev Pharmacol Toxicol 41: 297-316
31. Murray GI, Taylor MC, McFadyen MC, McKay JA, Greenlee WF, Burke MD, Melvin WT (1997) Tumor-specific expression of cytochrome P450 CYP1B1. Cancer Res 57: 3026-3031
32. Patterson AV, Barham HM, Chinje EC, Adams GE, Harris AL, Stratford IJ (1995) Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233). Br J Cancer 72: 1144-1150
33. Patterson LH, Murray GI (2002) Tumour cytochrome P450 and drug activation. Curr Pharm Des 8: 1335-1347
34. Potter GA, Patterson LH, Wanogho E, Perry PJ, Butler PC, Ijaz T, Ruparelia KC, Lamb JH, Farmer PB, Stanley LA, Burke MD (2002) The cancer preventative agent resveratrol is converted to the anticancer agent piceatannol by cytochrome P450 enzyme CYP1B1. Br J Cancer 86: 774-778
35. Rochat B, Morsman JM, Murray GI, Figg WD, McLeod HL (2001) Human CYP1B1 an anticancer agent metabolism: mechanism for tumor-specific drug inactivation? J Pharmacol Exp Ther 296: 537-541
36. Schwarz D, Roots I (2003) In vitro assessment of inhibition by natural polyphenols of metabolic activation of procarcinogens by human CYP1A1. Biochem Biophys Res Commun 303: 902-907
37. Shimada T, Hayes CL, Yamazaki H, Amin S, Hecht SS, Guengerich FP, Sutter TR (1996) Activation of chemically diverse procarcinogens by human cytochrome P-450 1B1. Cancer Res 56: 2979-2984
38. Shimada T, Gillam EM, Sutter TR, Strickland PT, Guengerich FP, Yamazaki H (1997) Oxidation of xenobiotics by recombinant human cytochrome P450 1B1. Drug Metab Dispos 25: 617-622
39. Shimada T, Yamazaki H, Foroozesh M, Hopkins NE, Alworth WL, Guengerich FP (1998) Selectivity of polycyclic inhibitors for human cytochrome P450s 1A1, 1A2, and 1B1. Chem Res Toxicol 11: 1048-1056
40. Stiborova M, Bieler CA, Wiessler M, Frei E (2001) The anticancer agent ellipticine on activation by cytochrome P450 forms covalent DNA adducts. Biochem Pharmacol 62: 1675-1684
41. Vermilion JL, Ballou DP, Massey V, Coon MJ (1981) Separate roles for FMN and FAD in catalysis by liver microsomal NADPH-cytochrome P-450 reductase. J Biol Chem 256: 266-277
42. Yagoda A, Abi-Rached B, Petrylak D (1995) Chemotherapy for advance renal-cell carcinoma; 1983-1993. Semin Oncol 22: 42-60
43. Yamazaki H, Komatsu T, Takemoto K, Shimada N, Nakajima M, Yokoi T (2001) Rat cytochrome P450 1A and 3A enzymes involved in bio-activation of tegafur to 5-fluorouracil and auto-induced by tegafur in liver microsomes. Drug Metab Dispos 29: 794-797